Answers are grounded in this paper and cite their sources.
Background Single-cell and spatial omics can inform research on immunotherapy response and resistance. We mapped publication activity and ClinicalTrials.gov study designs and explored evidence types in a targeted full-text subset of urologic cancer studies. Methods Web of Science Core Collection and Scopus records published in 2008–2025 were locked on 13 July 2026. Revision-stage eligibility reconciliation retained 538 records; 466 native Web of Science records supplied temporal-analysis inputs. A targeted full-text assessment was supplemented by a random audit of 100 previously non-selected records and independent reassessment of 40 selected studies. Evidence classes included treatment-exposed human data, association replication, computational proxies, experimental mechanisms, and prognosis. ClinicalTrials.gov records were analyzed separately. Results The 538-record corpus included 440 publications from 2023–2025 (81.8%). The targeted assessment included 122 original studies among 135 assessed reports. In the random audit, 15/100 records were C1 or C2b: three C1 and 12 C2b. One C1 report contained cell-level descriptive evidence without a patient-level marker–outcome analysis. The initial evidence-class agreement was 92/100 (Cohen’s kappa, 0.890) in this audit and 31/40 (kappa, 0.682) in the selected-study reassessment. Public-cohort reuse and exploratory analyses limited clinical interpretation. Of 10 ClinicalTrials.gov records, one had a verified reported omics component, eight documented planned or ongoing components, and one was withdrawn without accrual. Conclusion Bibliometric activity increased in the retained corpus. The random audit identified treatment-related reports missed by targeted retrieval, limiting claims about evidence completeness. Cell-level descriptions, patient-level associations, and locked-model validation require separate interpretation. Neither selected-study proportions nor bibliometric attention establishes field-wide clinical maturity. Registry plans require component-specific verification of implementation and reporting.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: